# Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

> **NCT01215357** · PHASE2 · COMPLETED · sponsor: **Emalex Biosciences Inc.** · enrollment: 34 (actual)

## Conditions studied

- Pathological Gambling

## Interventions

- **DRUG:** Ecopipam

## Key facts

- **NCT ID:** NCT01215357
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215357, "Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01215357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*